» Articles » PMID: 24320423

Sensitivity of Volumetric Modulated Arc Therapy Patient Specific QA Results to Multileaf Collimator Errors and Correlation to Dose Volume Histogram Based Metrics

Overview
Journal Med Phys
Specialty Biophysics
Date 2013 Dec 11
PMID 24320423
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: This study investigates the impact of systematic multileaf collimator (MLC) positional errors on gamma analysis results used for quality assurance (QA) of Rapidarc treatments. In addition, this study evaluates the relationship of these gamma analysis results and clinical dose volume histogram metrics (DVH) for Rapidarc treatment plans.

Methods: Five prostate plans were modified by the introduction of systematic MLC errors. The MLC shifts to each individual active leaf introduced were 0.25, 0.5, 0.75, and 1 mm. All QA verification plans were delivered and estimated 3D patient dose or high density phantom dose were obtained based on the ArcCHECK measurement files. QA gamma analysis of 3%/3 mm and 2%/2 mm were implemented and relationships to dose differences in DVH metrics encountered due to MLC errors were determined. Tolerances of 3% and 5% for DVH metric were implemented to determine the sensitivity of gamma analysis to MLC errors. A calculation of sensitivity was determined from the number of incidences of false negative and false positive cases in gamma analysis results.

Results: The sensitivity of global gamma analysis for criteria of 3%/3 mm was 0.78 and for 2%/2 mm was 0.82. A number of instances occurred for an acceptable VMAT QA gamma index which did not indicate a DVH metric dose error greater than 5%. The correlation between global gamma analysis using criteria 3%/3 mm and DVH metric dose error were all <0.8 indicating less than a strong correlation.

Conclusions: There is a greater sensitivity for detection of dosimetric errors occurring in a Rapidarc plan using gamma criteria of 2%/2 mm than 3%/3 mm. However, there is lack of consistently strong correlation between global gamma indexes and clinical DVH metrics for PTV and bladder and rectum for Rapidarc plans. It is recommended that the sole use of gamma index for Rapidarc QA plan evaluation could be insufficient and a methodology for evaluation of delivered dose to patient is required.

Citing Articles

Assessment of Statistical Process Control Based DVH Action Levels for Systematic Multi-Leaf Collimator Errors in Cervical Cancer RapidArc Plans.

Zhang H, Lu W, Cui H, Li Y, Yi X Front Oncol. 2022; 12:862635.

PMID: 35664736 PMC: 9157499. DOI: 10.3389/fonc.2022.862635.


Evaluation of the ability of three commercially available dosimeters to detect systematic delivery errors in step-and-shoot IMRT plans.

Gray A, Bawazeer O, Arumugam S, Vial P, Descallar J, Thwaites D Rep Pract Oncol Radiother. 2021; 26(5):793-803.

PMID: 34760314 PMC: 8575358. DOI: 10.5603/RPOR.a2021.0093.


Comparison of gamma index based on dosimetric error and clinically relevant dose-volume index based on three-dimensional dose prediction in breast intensity-modulated radiation therapy.

Kaneko A, Sumida I, Mizuno H, Isohashi F, Suzuki O, Seo Y Radiat Oncol. 2019; 14(1):36.

PMID: 30808377 PMC: 6390354. DOI: 10.1186/s13014-019-1233-0.


Patient-Specific Quality Assurance Protocol for Volumetric Modulated Arc Therapy using Dose Volume Histogram.

Low C, Toye W, Phung P, Huston C J Med Phys. 2018; 43(2):112-118.

PMID: 29962689 PMC: 6020622. DOI: 10.4103/jmp.JMP_138_17.


To propose adding index of achievement (IOA) to IMRT QA process.

Kim D, Kim S, Kang S, Kim T, Park S, Kim K Radiat Oncol. 2018; 13(1):112.

PMID: 29903025 PMC: 6003087. DOI: 10.1186/s13014-018-1055-5.